कैंडेसार्टन के इंटरैक्शन

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

…of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (एप्टिफिबाटाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Do not co-administer aliskiren with candesartan cilexetil in patients with diabetes [see Drug Interactions (7.4) ] . (कैंडेसार्टन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (क्लोज़ापिन लेबल, बॉक्स्ड चेतावनी)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

…coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (टैडालाफिल लेबल, चेतावनियां और सावधानियां)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

ये दवाएं पोटैशियम का उत्सर्जन कम करती हैं; इनके साथ पोटैशियम सप्लीमेंट या नमक के विकल्प (सॉल्ट सब्स्टीट्यूट) जोड़ने से हाइपरकेलेमिया हो सकता है, जो दिल की धड़कन की लय पर असर डालता है। (NIH Office of Dietary Supplements, Potassium)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (मिनोक्सिडिल लेबल, बॉक्स्ड चेतावनी)

Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (मेटोलाज़ोन लेबल, चेतावनियां)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (अल्फुज़ोसिन लेबल, चेतावनियां और सावधानियां)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (आर्मोडाफिनिल लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (इलोपेरिडोन लेबल, चेतावनियां और सावधानियां)

Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (एटेनोलोल लेबल, चेतावनियां)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (एटोमोक्सेटिन लेबल, दवाओं के इंटरैक्शन)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (एपोएटिन अल्फा लेबल, चेतावनियां और सावधानियां)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (एपोप्रोस्टेनोल लेबल, दवाओं के इंटरैक्शन)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (एरिपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

• Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (एवानाफिल लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (एसेनापिन लेबल, चेतावनियां और सावधानियां)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. (एस्मोलोल लेबल, दवाओं के इंटरैक्शन)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

…of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (ओलैंज़ापिन लेबल, चेतावनियां और सावधानियां)

…and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (ओलैंज़ापिन और फ्लुओक्सेटिन लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (कार्बिडोपा लेबल, दवाओं के इंटरैक्शन)

Antihypertensive drugs: May cause symptomatic postural hypotension. (कार्बिडोपा और लेवोडोपा लेबल, दवाओं के इंटरैक्शन)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (कार्बिडोपा, लेवोडोपा और एंटाकैपोन लेबल, दवाओं के इंटरैक्शन)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (कार्वेडिलोल लेबल, चेतावनियां और सावधानियां)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (कैरिप्राज़िन लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (क्वेटियापिन लेबल, चेतावनियां और सावधानियां)

Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (ज़िप्रासिडोन लेबल, चेतावनियां और सावधानियां)

Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (टेराज़ोसिन लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (टेस्टोस्टेरोन लेबल, चेतावनियां और सावधानियां)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (टैक्रोलिमस लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Monitor serum potassium during concomitant therapy with ( 7.2 ): Angiotensin receptor blockers Angiotensin converting enzyme inhibitors Potassium sparing diuretics 7.1 CYP3A Inhibitors and Inducers Strong CYP3A Inhibitors Tolvaptan's AUC was 5.4 times as large and C max was 3.5 times as large after co-administration of tolvaptan and 200 mg ketoconazole [see Warnings… (टोल्वैप्टन लेबल, दवाओं के इंटरैक्शन)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (डुलोक्सेटिन लेबल, चेतावनियां और सावधानियां)

• Antihypertensive Drugs: Monitor blood pressure. (डेक्समिथाइलफेनिडेट लेबल, दवाओं के इंटरैक्शन)

Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (ड्रोस्पिरेनोन और एथिनिल एस्ट्राडियोल लेबल, चेतावनियां और सावधानियां)

Antihypertensives: Possible additive hypotensive effects. (नाइट्रोग्लिसरीन लेबल, दवाओं के इंटरैक्शन)

Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (निमोडिपिन लेबल, दवाओं के इंटरैक्शन)

Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (नियासिन लेबल, दवाओं के इंटरैक्शन)

Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (पाज़ोपैनिब लेबल, चेतावनियां और सावधानियां)

Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (पेंटोक्सिफाइलिन लेबल, दवाओं के इंटरैक्शन)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (पैलिपेरिडोन लेबल, चेतावनियां और सावधानियां)

Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (प्राज़ोसिन लेबल, चेतावनियां)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

…hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (फेनेलज़िन लेबल, चेतावनियां)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (बिसोप्रोलोल लेबल, चेतावनियां)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (बोर्टेज़ोमिब लेबल, चेतावनियां और सावधानियां)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (ब्रिमोनिडिन लेबल, दवाओं के इंटरैक्शन)

Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (ब्रिमोनिडिन और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Use caution in patients taking antihypertensive medications. (ब्रोमोक्रिप्टिन लेबल, चेतावनियां और सावधानियां)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Antihypertensive Drugs: Monitor blood pressure. (मिथाइलफेनिडेट लेबल, दवाओं के इंटरैक्शन)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

REMERON/REMERONSolTab should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication). (मिर्टाज़ापिन लेबल, चेतावनियां और सावधानियां)

The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (मेकामाइलामिन लेबल, दवाओं के इंटरैक्शन)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (रियोसिगुआट लेबल, चेतावनियां और सावधानियां)

Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Lithium: Increases in serum lithium concentrations and toxicity ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (लुमाटेपेरोन लेबल, चेतावनियां और सावधानियां)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (ल्यूरासिडोन लेबल, चेतावनियां और सावधानियां)

Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (वार्डेनाफिल लेबल, दवाओं के इंटरैक्शन)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

…concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (साइक्लोबेंज़ाप्रिन लेबल, दवाओं के इंटरैक्शन)

Caution is also required when cyclosporine is coadministered with potassium sparing drugs (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists), potassium-containing drugs as well as in patients on a potassium rich diet. (साइक्लोस्पोरिन लेबल, दवाओं के इंटरैक्शन)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (सिलोडोसिन लेबल, चेतावनियां और सावधानियां)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (सिल्डेनाफिल लेबल, चेतावनियां और सावधानियां)

Initiate and/or adjust antihypertensive therapy as appropriate. (सुनिटिनिब लेबल, चेतावनियां और सावधानियां)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (सोराफेनिब लेबल, चेतावनियां और सावधानियां)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (कैंडेसार्टन लेबल, दवाओं के इंटरैक्शन)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (इकाटिबेंट लेबल, दवाओं के इंटरैक्शन)

In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect. (इसराडिपिन लेबल, दवाओं के इंटरैक्शन)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (क्लोरप्रोमाज़िन लेबल, चेतावनियां)

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. (ट्राइफ्लुओपेराज़िन लेबल, सावधानियां)

Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting compounds. (डेसिप्रामिन लेबल, चेतावनियां)

If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (डेसोजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, चेतावनियां)

Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be more sensitive to the effects of sodium nitroprusside than normal subjects. (नाइट्रोप्रुसाइड लेबल, चेतावनियां)

Candesartan: No significant drug interaction has been reported in studies with candesartan cilexitil given together with nifedipine. (निफेडिपिन लेबल, दवाओं के इंटरैक्शन)

The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. (निसोल्डिपिन लेबल, दवाओं के इंटरैक्शन)

The antihypertensive action of guanethidine and similar agents may be blocked. (नॉरट्रिप्टिलीन लेबल, चेतावनियां)

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. (प्रोक्लोरपेराज़िन लेबल, सावधानियां)

Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (प्रोट्रिप्टिलीन लेबल, चेतावनियां)

In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (ब्यूटॉर्फेनॉल लेबल, चेतावनियां)

Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (मिथाइलडोपा लेबल, दवाओं के इंटरैक्शन)

In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (मेक्सिलेटिन लेबल, दवाओं के इंटरैक्शन)

Because of its relative beta 1 cardio-selectivity, however, Metoprolol Tartrate Tablets may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (मेटोप्रोलोल लेबल, चेतावनियां और सावधानियां)

When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. (हाइड्रालाज़िन लेबल, दवाओं के इंटरैक्शन)